Entering text into the input field will update the search result below

Entheon Biomedical begins enrollment in phase 1 study of DMT for addiction disorders

Mar. 15, 2022 11:00 AM ETEntheon Biomedical Corp. (ENTBF) StockBy: Ravikash Bakolia, SA News Editor

Neuron system disease

koto_feja/E+ via Getty Images

  • Entheon Biomedical (OTCQB:ENTBF) said the first patient was enrolled in a phase 1 trial called EBRX-101 evaluating N, N-dimethyltryptamine (DMT) for addiction disorders.
  • In the study — which is being conducted at the Centre for Human Drug Research

Recommended For You

More Trending News

About ENTBF Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ENTBF--
Entheon Biomedical Corp.